Change of date for publication of the year-end report for the financial year 2025

SciBase Holding AB has postponed the publication of its 2025 year-end report to March 13, 2026 to align the trading restriction period with an ongoing rights issue whose subscription period ends January 26, 2026. The announcement is procedural and contains no financial results; investors should monitor the rights issue and the adjusted reporting timetable for potential implications to liquidity and shareholder positioning.

Analysis

Market structure: The rights issue and delayed year‑end report signal a near‑term liquidity recapitalization for SciBase (SciBase Holding AB, Nasdaq First North). Direct losers are non‑participating retail holders (dilution risk) and short‑term lenders; winners are subscribers able to buy at the rights price and the company if the raise stabilizes operations. Expect downward pressure on free float and heavier bid/ask spreads for 2–8 weeks post‑allocation as new shares trade and information asymmetry persists.

Risk assessment: Tail risks include a failed rights issue triggering emergency bridge financing or insolvency (low probability, high impact) and regulatory scrutiny for delayed reporting (moderate). Immediate (days): volatility around subscription results; short‑term (weeks–months): share issuance and cash runway transparency; long‑term (quarters–years): commercial uptake of Nevisense determines survival. Hidden dependencies: success depends on reimbursements, clinic adoption rates, and CE/US pathway milestones that are not addressed by the raise.

Trade implications: For liquid execution, prefer small, size‑controlled positions: conditional long exposure only if pro‑rata subscription economics deliver >=30% implied upside and extend runway to >=12 months; otherwise avoid or short base case. Use options where available: buy 3‑month puts to hedge existing exposure or construct a calendar spread to monetize elevated near‑term volatility ahead of the March 13 report. Rotate away from small‑cap Nordic medtechs into larger, profitable device names (e.g., MDT, ISRG) to reduce idiosyncratic funding risk.

Contrarian angles: Consensus treats the event as pure dilution; that may underweight the binary upside if the raise funds accelerated commercial rollout—post‑money valuation could re‑rate if Nevisense secures two large hospital contracts or reimbursement decisions within 6–12 months. Historical parallels: small medtech rights issues often compress price by 30–60% then recover on execution; exploit this with disciplined size and strict stop losses rather than conviction buys blind to funding metrics.

Key Decisions for Investors

• If holding SciBase, establish a 1–3% portfolio-sized hedge by buying 3‑month AT‑the‑money (or nearest available) puts to limit downside to ~10–15% while awaiting subscription allocation and the March 13 report.
• Participate in the rights issue only up to pro‑rata entitlement if the subscription price implies >=30% post‑money upside vs. the last traded price AND the company discloses a pro‑forma cash runway >=12 months; otherwise decline participation and reduce exposure to zero within 30 days.
• For opportunistic traders: consider a 0.5–1% tactical long if post‑raise free float tightens and the company announces ≥SEK 50–100M fresh capital or a named hospital contract within 60 days; target 50–100% upside, stop at -30%.
• Reduce small‑cap Nordic medtech exposure by 2–4% and redeploy into large, cash‑generative device names (examples: MDT, ISRG) to lower idiosyncratic funding risk over the next 3–12 months.
• Monitor three explicit catalysts in the next 30–90 days before adding: final subscription tally, prospectus with number of new shares and subscription price, and updated pro‑forma cash runway; do not increase gross exposure without all three.